Patient-centered approach to elicit and compare the treatment goals of patients with tardive dyskinesia, their care partners, and healthcare providers
Objective: To elicit and compare the treatment goals of patients with tardive dyskinesia (TD), their care partners, and healthcare providers (HCP). Background: Tardive dyskinesia (TD)…Long-Term Outcomes with Valbenazine 40 mg/day in Adults with Tardive Dyskinesia
Objective: To examine long-term outcomes in adults with tardive dyskinesia (TD) who received once-daily valbenazine (VBZ) 40 mg or had a dose reduction from 80…Clonazepam as a cure or a cause? : Withdrawal Emergent Syndrome
Objective: To report a case of clonazepam induced withdrawal emergent dyskinesia. Background: Withdrawal emergent syndrome was first described in 1973 when it was noticed that…A case of tardive dyskinesia and parkinsonism following use of phentermine for weight loss
Objective: To describe a case of tardive dyskinesia and parkinsonism following use of phentermine and briefly review the literature on tardive syndromes following use of…Global Improvement and Patient Satisfaction: Results from a Long-Term, Open-Label, Rollover Study of Valbenazine in Tardive Dyskinesia
Objective: To assess global improvement and patient satisfaction in participants with tardive dyskinesia (TD) who received long-term treatment with once-daily valbenazine (VBZ). Background: VBZ, approved…Hospital Utilization Rates Following Antipsychotic Dose Reductions Among Patients With Bipolar and Major Depressive Disorders
Objective: To analyze the healthcare burden and incidence of Tardive dyskinesia (TD) due to antipsychotic dose reduction in patients with bipolar disorder (BD) and major…Assessing the Effectiveness of Valbenazine in the Treatment of Tardive Dyskinesia as Determined by the AIMS and PGIC: Results from the KINECT 4 Trial
Objective: To assess the long-term effects of once-daily valbenazine on tardive dyskinesia (TD). Background: Valbenazine has been evaluated in several long-term TD studies, including the…Abnormal signaling along the non-canonical molecular cascade GRK6/β-arrestin2/Akt/GSK-3β in the putamen is associated with tardive dyskinesia following chronic haloperidol exposure in a primate model
Objective: To investigate the neurochemical basis of tardive dyskinesia (TD) in an experimental primate model. Background: TD is a potentially irreversible motor complication occurring in…Tardive Myoclonus: A Case Report
Objective: To report a patient with late-onset myoclonus after treatment with antipsychotic drugs which is a rare variant of tardive movement disorders. Background: The use…Effects of Long-Term Valbenazine on Tardive Dyskinesia by Body Region: Shift Analyses of KINECT 4 Study Results
Objective: To assess clinically meaningful improvements in tardive dyskinesia (TD) by evaluating changes in abnormal movements by body region after long-term valbenazine (VBZ) treatment. Background:…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- 8
- Next Page »